Definium Therapeutics (DFTX) Phase 3 Trial Success: A Potential Game Changer for Anxiety Treatment
Definium Therapeutics' successful Phase 3 trial results could reshape anxiety treatment and boost investor sentiment.
Clean Harbors Expands Footprint with $470 Million EnviroServe Acquisition
Clean Harbors is set to bolster its environmental services capabilities with the $470 million acquisition of EnviroServe.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Definium Therapeutics Soars on Trial Success: What This Means for Investors
Definium Therapeutics stock surged 20% following positive Phase 3 trial results, signaling a significant de-risking even…
Regulatory Concerns Hit Neurocrine Biosciences: A Closer Look at NBIX's Safety Woes
Neurocrine Biosciences faces scrutiny after seven patient deaths linked to its drug raise regulatory alarm bells.
Nasdaq's Strategic Acquisition of LeveL Markets: Implications for 24/7 Trading
Nasdaq's acquisition of LeveL Markets signals a major shift towards extended trading hours, reshaping market infrastruct…
AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades
AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adju…
Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment
Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatment and investor int…
H&R REIT's C$6.7 Billion Take-Private: A Game Changer for Canadian Real Estate?
H&R REIT's C$6.7 billion acquisition could reshape the Canadian commercial real estate landscape.
Thoma Bravo's C$650M Acquisition of Kneat: What It Means for the Canadian Tech Landscape
Thoma Bravo's C$650M acquisition of Kneat signals a pivotal shift in the Canadian tech market amidst evolving private eq…
PDS Biotech Shifts Focus to PDS0301: Implications for Investors
PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.
Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhancing its R&D and com…